Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) Insider Sells $45,675.00 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) insider Sherry Korczynski sold 8,750 shares of Aquestive Therapeutics stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total value of $45,675.00. Following the completion of the transaction, the insider owned 235,689 shares in the company, valued at $1,230,296.58. The trade was a 3.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Aquestive Therapeutics Trading Down 4.3%

NASDAQ:AQST traded down $0.21 during mid-day trading on Friday, hitting $4.78. 2,295,311 shares of the company’s stock traded hands, compared to its average volume of 3,068,932. Aquestive Therapeutics, Inc. has a 12 month low of $2.93 and a 12 month high of $7.55. The firm has a market capitalization of $599.31 million, a price-to-earnings ratio of -7.32 and a beta of 1.48. The firm has a 50 day moving average of $4.38 and a two-hundred day moving average of $4.25.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The firm had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. As a group, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.5 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of AQST. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics in the third quarter valued at $28,000. BNP Paribas Financial Markets grew its holdings in shares of Aquestive Therapeutics by 78.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares during the last quarter. Modern Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics in the 2nd quarter worth about $33,000. Elevation Point Wealth Partners LLC acquired a new stake in shares of Aquestive Therapeutics during the 1st quarter worth about $42,000. Finally, ADAR1 Capital Management LLC lifted its holdings in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after purchasing an additional 264,000 shares during the last quarter. Institutional investors own 32.45% of the company’s stock.

Wall Street Analyst Weigh In

AQST has been the topic of several research reports. Wall Street Zen downgraded shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research report on Monday, August 24th. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Aquestive Therapeutics in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $9.17.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.